NCT07046975View on ClinicalTrials.gov

Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone

PHASE3RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 15, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

November 30, 2026

Conditions
Bioavailability Heathy Volunteers
Interventions
DRUG

Torsemide and Spironolactone tablet

Fixed Dose Combination (FDC): (12 mg Extended Release (ER) Torsemide and 15 mg Spironolactone) tablet

DRUG

Torsemide Tablets and Spironolactone Tablets

10 mg Torsemide tablet and 25 mg Spironolactone tablet given together

Trial Locations (1)

22182

RECRUITING

Sarfez Pharmaceuticals, Vienna

All Listed Sponsors
lead

Sarfez Pharmaceuticals, Inc.

INDUSTRY